Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
ChemoCentryx Stock Price (Quote) NASDAQ:CCXI
$22.79 ( 3.36% ) Friday, 20th May 2022
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $14.95 | $23.28 | Friday, 20th May 2022 CCXI stock ended at $22.79. This is 3.36% more than the trading day before Thursday, 19th May 2022. During the day the stock fluctuated 7.73% from a day low at $21.61 to a day high of $23.28. |
| 90 days | $14.95 | $31.46 | |
| 52 weeks | $9.53 | $42.16 |
Historical ChemoCentryx prices
| Date | Open | High | Low | Close | Volume |
| 2022-05-20 | $22.12 | $23.28 | $21.61 | $22.79 | 1 941 201 |
| 2022-05-19 | $20.79 | $22.90 | $20.79 | $22.05 | 2 214 081 |
| 2022-05-18 | $20.00 | $21.44 | $19.83 | $20.86 | 1 499 189 |
| 2022-05-17 | $19.66 | $21.01 | $19.44 | $20.91 | 1 329 427 |
| 2022-05-16 | $19.14 | $20.37 | $18.75 | $19.20 | 1 178 727 |
| 2022-05-13 | $17.82 | $19.18 | $17.62 | $19.17 | 1 341 547 |
| 2022-05-12 | $16.21 | $17.63 | $16.16 | $17.35 | 1 362 769 |
| 2022-05-11 | $17.83 | $18.69 | $16.49 | $16.49 | 2 207 322 |
| 2022-05-10 | $16.16 | $18.12 | $15.31 | $17.89 | 3 332 105 |
| 2022-05-09 | $16.81 | $17.03 | $14.95 | $15.36 | 2 702 153 |
| 2022-05-06 | $18.26 | $19.48 | $17.19 | $17.38 | 8 446 652 |
| 2022-05-05 | $16.67 | $16.89 | $15.28 | $15.64 | 1 984 488 |
| 2022-05-04 | $17.82 | $17.82 | $16.16 | $16.99 | 2 592 886 |
| 2022-05-03 | $18.70 | $18.96 | $17.51 | $17.68 | 1 447 237 |
| 2022-05-02 | $18.55 | $19.05 | $17.76 | $18.77 | 1 694 682 |
| 2022-04-29 | $18.90 | $19.40 | $18.36 | $18.46 | 1 151 609 |
| 2022-04-28 | $19.41 | $19.41 | $17.90 | $19.04 | 903 423 |
| 2022-04-27 | $19.25 | $19.76 | $18.82 | $19.07 | 815 782 |
| 2022-04-26 | $19.70 | $19.76 | $19.12 | $19.19 | 1 446 174 |
| 2022-04-25 | $19.10 | $20.03 | $19.01 | $19.84 | 823 840 |
| 2022-04-22 | $21.11 | $21.37 | $19.34 | $19.49 | 490 470 |
| 2022-04-21 | $21.11 | $21.40 | $19.53 | $19.69 | 1 050 300 |
| 2022-04-20 | $21.21 | $21.71 | $20.75 | $20.88 | 1 089 300 |
| 2022-04-19 | $20.80 | $21.87 | $20.53 | $21.20 | 1 316 500 |
| 2022-04-18 | $21.43 | $21.43 | $20.39 | $20.69 | 1 174 400 |
| 2022-04-14 | $22.10 | $22.20 | $21.17 | $21.55 | 934 430 |
| 2022-04-13 | $22.13 | $22.41 | $21.16 | $22.15 | 1 353 721 |
| 2022-04-12 | $22.25 | $22.50 | $20.69 | $21.16 | 1 543 637 |
| 2022-04-11 | $22.70 | $22.90 | $21.79 | $21.94 | 756 542 |
| 2022-04-08 | $23.71 | $23.92 | $22.75 | $22.91 | 891 800 |
| 2022-04-07 | $24.17 | $24.78 | $23.36 | $23.81 | 1 494 200 |
| 2022-04-06 | $24.39 | $24.78 | $23.86 | $24.20 | 3 054 000 |
| 2022-04-05 | $26.25 | $26.29 | $24.70 | $24.74 | 755 300 |
| 2022-04-04 | $26.86 | $27.03 | $25.64 | $26.27 | 1 358 300 |
| 2022-04-01 | $25.32 | $26.77 | $25.02 | $26.71 | 876 542 |
| 2022-03-31 | $25.13 | $25.60 | $24.89 | $25.07 | 477 186 |
| 2022-03-30 | $25.62 | $26.43 | $24.83 | $25.01 | 516 692 |
| 2022-03-29 | $24.51 | $25.87 | $24.34 | $25.71 | 1 016 600 |
| 2022-03-28 | $24.14 | $24.68 | $23.55 | $24.33 | 549 800 |
| 2022-03-25 | $24.30 | $24.30 | $23.28 | $23.96 | 630 200 |
| 2022-03-24 | $23.97 | $24.65 | $23.54 | $24.45 | 462 800 |
| 2022-03-23 | $24.65 | $25.15 | $23.80 | $23.86 | 645 400 |
| 2022-03-22 | $24.27 | $25.00 | $24.25 | $24.96 | 599 629 |
| 2022-03-21 | $25.53 | $25.62 | $24.06 | $24.31 | 601 354 |
| 2022-03-18 | $25.07 | $25.97 | $24.82 | $25.56 | 1 798 020 |
| 2022-03-17 | $24.17 | $25.29 | $23.63 | $25.25 | 1 003 700 |
| 2022-03-16 | $23.13 | $24.19 | $22.93 | $24.17 | 877 800 |
| 2022-03-15 | $22.26 | $23.26 | $22.11 | $22.91 | 805 700 |
| 2022-03-14 | $23.73 | $24.17 | $21.77 | $22.22 | 1 598 500 |
| 2022-03-11 | $25.00 | $25.55 | $23.70 | $23.72 | 799 500 |
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders, and cancer in the United States. Its lead drug candidates in clinical development include CCX168, which is in Phase II clinical trials for the treatment of orphan and rare diseases; CCX872, which is in Phase I... Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
